• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

在首次缓解6年后，本妥昔单抗单药治疗经典型霍奇金淋巴瘤晚期复发取得成功。

Successful brentuximab vedotin monotherapy against late relapse of classical Hodgkin lymphoma 6 years after first remission.

作者信息

Nagashima Kana, Kikuchi Shohei, Iyama Satoshi, Fujita Chisa, Goto Akari, Horiguchi Hiroto, Kobune Masayoshi

机构信息

Department of Hematology Sapporo Medical University School of Medicine Sapporo Japan.

出版信息

Clin Case Rep. 2020 Jan 31;8(3):466-468. doi: 10.1002/ccr3.2688. eCollection 2020 Mar.

DOI:10.1002/ccr3.2688
PMID:32185037
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7069848/
Abstract

Brentuximab vedotin monotherapy for late-relapse CHL is a promising therapeutic with sustained CR benefit and avoiding potential toxicities caused by aPBSCT/HDT.

摘要

本妥昔单抗单药治疗晚期复发的经典型霍奇金淋巴瘤是一种有前景的疗法，可带来持续的完全缓解益处，并避免自体造血干细胞移植/高剂量化疗引起的潜在毒性。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/93c8/7069848/f8950f3bfa9c/CCR3-8-466-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/93c8/7069848/7ac96df66ded/CCR3-8-466-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/93c8/7069848/9b7e6347fd46/CCR3-8-466-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/93c8/7069848/f8950f3bfa9c/CCR3-8-466-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/93c8/7069848/7ac96df66ded/CCR3-8-466-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/93c8/7069848/9b7e6347fd46/CCR3-8-466-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/93c8/7069848/f8950f3bfa9c/CCR3-8-466-g003.jpg

相似文献

1
Successful brentuximab vedotin monotherapy against late relapse of classical Hodgkin lymphoma 6 years after first remission.在首次缓解6年后，本妥昔单抗单药治疗经典型霍奇金淋巴瘤晚期复发取得成功。
Clin Case Rep. 2020 Jan 31;8(3):466-468. doi: 10.1002/ccr3.2688. eCollection 2020 Mar.
2
The Role of Brentuximab Vedotin (BV) as Second-Line Treatment of Refractory Classical Hodgkin Lymphoma (cHL) in the Era of Pandemic COVID-19.在新冠疫情大流行时代，维布妥昔单抗（BV）作为难治性经典型霍奇金淋巴瘤（cHL）二线治疗的作用
Int Med Case Rep J. 2022 Jun 1;15:269-273. doi: 10.2147/IMCRJ.S348718. eCollection 2022.
3
Brentuximab vedotin in relapsed/refractory Hodgkin lymphoma post-autologous transplant: meta-analysis versus historical data.自体移植后复发/难治性霍奇金淋巴瘤中维布妥昔单抗治疗：荟萃分析与历史数据对比
Curr Med Res Opin. 2015 May;31(5):993-1001. doi: 10.1185/03007995.2015.1030378. Epub 2015 Apr 9.
4
[Brentuximab vedotin treatment in patients with relapsed or refractory Hodgkin lymphoma. A Hungarian retrospective study].[复发或难治性霍奇金淋巴瘤患者的本妥昔单抗治疗。一项匈牙利回顾性研究]
Orv Hetil. 2017 Oct;158(41):1630-1634. doi: 10.1556/650.2017.30867.
5
Pembrolizumab versus brentuximab vedotin in relapsed or refractory classical Hodgkin lymphoma (KEYNOTE-204): an interim analysis of a multicentre, randomised, open-label, phase 3 study.帕博利珠单抗对比本妥昔单抗维布妥昔单抗治疗复发或难治性经典型霍奇金淋巴瘤（KEYNOTE-204）：一项多中心、随机、开放标签、3 期研究的中期分析。
Lancet Oncol. 2021 Apr;22(4):512-524. doi: 10.1016/S1470-2045(21)00005-X. Epub 2021 Mar 12.
6
Real-world efficacy of brentuximab vedotin plus bendamustine as a bridge to autologous hematopoietic stem cell transplantation in primary refractory or relapsed classical Hodgkin lymphoma.原发性难治性或复发性经典霍奇金淋巴瘤患者应用本妥昔单抗维泊妥珠单抗联合苯达莫司汀桥接自体造血干细胞移植的真实世界疗效。
Ann Hematol. 2020 Oct;99(10):2385-2392. doi: 10.1007/s00277-020-04204-1. Epub 2020 Aug 3.
7
Brentuximab vedotin plus AVD followed by involved-node radiotherapy in a patient with classic Hodgkin lymphoma following gray zone lymphoma after autologous stem-cell transplantation failure.自体造血干细胞移植失败后继发灰色区淋巴瘤后，患者接受 Brentuximab vedotin 联合 AVD 方案治疗及受累淋巴结放疗。
Hematology. 2023 Dec;28(1):2207946. doi: 10.1080/16078454.2023.2207946.
8
[Brentuximab vedotin and immune checkpoint inhibitors for the treatment of Hodgkin lymphoma].[注射用维布妥昔单抗与免疫检查点抑制剂治疗霍奇金淋巴瘤]
Rinsho Ketsueki. 2020;61(8):890-900. doi: 10.11406/rinketsu.61.890.
9
Dose-dense brentuximab vedotin plus ifosfamide, carboplatin, and etoposide for second-line treatment of relapsed or refractory classical Hodgkin lymphoma: a single centre, phase 1/2 study.达雷妥尤单抗联合异环磷酰胺、卡铂和依托泊苷治疗二线复发或难治性经典型霍奇金淋巴瘤：一项单中心、1/2 期研究。
Lancet Haematol. 2021 Aug;8(8):e562-e571. doi: 10.1016/S2352-3026(21)00170-8.
10
Where does brentuximab vedotin fit into the management of patients with Hodgkin lymphoma?本妥昔单抗维迪西妥单抗在霍奇金淋巴瘤患者的治疗管理中处于什么位置？
Curr Hematol Malig Rep. 2012 Sep;7(3):179-85. doi: 10.1007/s11899-012-0126-1.

引用本文的文献

1
The Role of Brentuximab Vedotin (BV) as Second-Line Treatment of Refractory Classical Hodgkin Lymphoma (cHL) in the Era of Pandemic COVID-19.在新冠疫情大流行时代，维布妥昔单抗（BV）作为难治性经典型霍奇金淋巴瘤（cHL）二线治疗的作用
Int Med Case Rep J. 2022 Jun 1;15:269-273. doi: 10.2147/IMCRJ.S348718. eCollection 2022.

本文引用的文献

1
Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin's Lymphoma.本妥昔单抗联合化疗治疗Ⅲ期或Ⅳ期霍奇金淋巴瘤
N Engl J Med. 2018 Jan 25;378(4):331-344. doi: 10.1056/NEJMoa1708984. Epub 2017 Dec 10.
2
Late Relapse of Classical Hodgkin Lymphoma: An Analysis of the German Hodgkin Study Group HD7 to HD12 Trials.经典型霍奇金淋巴瘤的晚期复发：德国霍奇金研究组 HD7 至 HD12 试验分析。
J Clin Oncol. 2017 May 1;35(13):1444-1450. doi: 10.1200/JCO.2016.71.3289. Epub 2017 Feb 27.
3
Five-year survival and durability results of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma.
复发或难治性霍奇金淋巴瘤患者使用维布妥昔单抗的5年生存率和疗效持久性结果
Blood. 2016 Sep 22;128(12):1562-6. doi: 10.1182/blood-2016-02-699850. Epub 2016 Jul 18.
4
High-dose chemotherapy followed by autologous stem cell transplantation for patients with relapsed/refractory Hodgkin lymphoma.复发/难治性霍奇金淋巴瘤患者接受大剂量化疗后进行自体干细胞移植。
Cochrane Database Syst Rev. 2013 Jun 20;2013(6):CD009411. doi: 10.1002/14651858.CD009411.pub2.
5
Randomized phase III trial of ABVD versus Stanford V with or without radiation therapy in locally extensive and advanced-stage Hodgkin lymphoma: an intergroup study coordinated by the Eastern Cooperative Oncology Group (E2496).ABVD 方案与 Stanford V 方案联合或不联合放疗治疗局部广泛期和晚期霍奇金淋巴瘤的随机 III 期临床试验：东部肿瘤协作组（E2496）协调的一项多中心研究。
J Clin Oncol. 2013 Feb 20;31(6):684-91. doi: 10.1200/JCO.2012.43.4803. Epub 2012 Nov 26.
6
Late effects after autologous hematopoietic cell transplantation.自体造血细胞移植后的晚期效应
Biol Blood Marrow Transplant. 2009 Jan;15(1 Suppl):21-4. doi: 10.1016/j.bbmt.2008.10.009.
7
Late mortality in survivors of autologous hematopoietic-cell transplantation: report from the Bone Marrow Transplant Survivor Study.自体造血细胞移植幸存者的晚期死亡率：来自骨髓移植幸存者研究的报告。
Blood. 2005 Jun 1;105(11):4215-22. doi: 10.1182/blood-2005-01-0035. Epub 2005 Feb 8.
8
Long-term results of conventional-dose salvage chemotherapy in patients with refractory and relapsed Hodgkin's disease (Croatian experience).难治性和复发性霍奇金淋巴瘤患者接受常规剂量挽救化疗的长期结果（克罗地亚经验）
Ann Oncol. 2002 Oct;13(10):1650-5. doi: 10.1093/annonc/mdf271.
9
Stanford V and radiotherapy for locally extensive and advanced Hodgkin's disease: mature results of a prospective clinical trial.斯坦福Ⅴ方案联合放疗治疗局部广泛及晚期霍奇金淋巴瘤：一项前瞻性临床试验的成熟结果
J Clin Oncol. 2002 Feb 1;20(3):630-7. doi: 10.1200/JCO.2002.20.3.630.
10
New prognostic score based on treatment outcome of patients with relapsed Hodgkin's lymphoma registered in the database of the German Hodgkin's lymphoma study group.基于德国霍奇金淋巴瘤研究组数据库中复发霍奇金淋巴瘤患者治疗结果的新预后评分。
J Clin Oncol. 2002 Jan 1;20(1):221-30. doi: 10.1200/JCO.2002.20.1.221.